| Literature DB >> 36272977 |
Dong-Keon Lee1, Taesam Kim1, Junyoung Byeon2, Minsik Park1, Suji Kim1, Joohwan Kim1, Seunghwan Choi1, Gihwan Lee3, Chanin Park3, Keun Woo Lee4, Yong Jung Kwon5, Jeong-Hyung Lee2, Young-Guen Kwon6, Young-Myeong Kim7.
Abstract
Regulated in development and DNA damage response 1 (REDD1) expression is upregulated in response to metabolic imbalance and obesity. However, its role in obesity-associated complications is unclear. Here, we demonstrate that the REDD1-NF-κB axis is crucial for metabolic inflammation and dysregulation. Mice lacking Redd1 in the whole body or adipocytes exhibited restrained diet-induced obesity, inflammation, insulin resistance, and hepatic steatosis. Myeloid Redd1-deficient mice showed similar results, without restrained obesity and hepatic steatosis. Redd1-deficient adipose-derived stem cells lost their potential to differentiate into adipocytes; however, REDD1 overexpression stimulated preadipocyte differentiation and proinflammatory cytokine expression through atypical IKK-independent NF-κB activation by sequestering IκBα from the NF-κB/IκBα complex. REDD1 with mutated Lys219/220Ala, key amino acid residues for IκBα binding, could not stimulate NF-κB activation, adipogenesis, and inflammation in vitro and prevented obesity-related phenotypes in knock-in mice. The REDD1-atypical NF-κB activation axis is a therapeutic target for obesity, meta-inflammation, and metabolic complications.Entities:
Year: 2022 PMID: 36272977 DOI: 10.1038/s41467-022-34110-1
Source DB: PubMed Journal: Nat Commun ISSN: 2041-1723 Impact factor: 17.694